Skip to Content

Ammonul (sodium benzoate / sodium phenylacetate) Disease Interactions

There are 7 disease interactions with Ammonul (sodium benzoate / sodium phenylacetate):

Major

Sodium salts (applies to Ammonul) sodium/water imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Hypernatremia, Hypokalemia, Fluid Retention, Congestive Heart Failure

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

References

  1. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
  3. "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.
Moderate

Phenylacetate/benzoate (applies to Ammonul) heart failure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Congestive Heart Failure

The combination product of sodium phenylacetate and sodium benzoate injection 10%/10% contains 30.5 mg of sodium per mL of undiluted product. Sodium phenylacetate and sodium benzoate injection should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema. It is recommended to discontinue administration of sodium phenylacetate and sodium benzoate injection, 10%/10%, evaluate the patient, and institute appropriate therapeutic countermeasures as appropriate.

Moderate

Phenylacetate/benzoate (applies to Ammonul) hypokalemia

Moderate Potential Hazard, Moderate plausibility.

Potassium levels should be carefully monitored as the excretion of the non-reabsorbable anions, phenylacetylglutamine and hippurate can enhance urine potassium loss. Care should be taken when using products containing sodium phenylacetate and sodium benzoate in patients with low blood potassium levels.

Moderate

Phenylacetate/benzoate (applies to Ammonul) neurotoxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Peripheral Neuropathy, Autonomic Neuropathy

The administration of intravenous phenylacetate may cause neurotoxicity. It is recommended to exercise care when using products containing sodium phenylacetate and sodium benzoate in cancer patients or in patients with neurotoxic disorders.

Moderate

Phenylacetate/benzoate (applies to Ammonul) renal/liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. It is recommended to use caution and close monitoring when using products containing sodium phenylacetate and sodium benzoate in patients with impaired renal function and in patients with hepatic insufficiency.

Moderate

Sodium benzoate (applies to Ammonul) acid/base imbalance

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Acidosis

Sodium benzoate is structurally similar to salicylates and mild respiratory alkalosis may occur. Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.

References

  1. "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.
Moderate

Sodium benzoate (applies to Ammonul) GI mucosal damage

Moderate Potential Hazard, Low plausibility. Applicable conditions: Peptic Ulcer

Sodium benzoate is structurally similar to salicylates and exacerbation of peptic ulcers may occur. Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to peptic ulcer disease.

References

  1. "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.

Ammonul (sodium benzoate / sodium phenylacetate) drug interactions

There are 3 drug interactions with Ammonul (sodium benzoate / sodium phenylacetate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.